Paper41337752
Selectivity of the Time-Dependent M. tuberculosis LeuRS Inhibitor Ganfeborole Is Driven by Target Vulnerability.
Wang M and 8 others. ACS Chem Biol, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Selectivity of the Time-Dependent M. tuberculosis LeuRS Inhibitor Ganfeborole Is Driven by Target Vulnerability. Papers, record 41337752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41337752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Selectivity of the Time-Dependent M. tuberculosis LeuRS Inhibitor Ganfeborole Is Driven by Target Vulnerability.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mycobacterium tuberculosis | Major topic |
| Leucine-tRNA Ligase | Major topic |
| Antitubercular Agents | Major topic |
| Boron Compounds | Major topic |
| Enzyme Inhibitors | Major topic |
| Escherichia coli | |
| Microbial Sensitivity Tests |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R35 GM149297 | NIGMS NIH HHS | United States | R35GM149297 | PubMed and NIH | NIH RePORTER |
| T32 GM136572 | NIGMS NIH HHS | United States | T32GM136572 | PubMed and NIH | NIH RePORTER |
| T32 GM148331 | NIGMS NIH HHS | United States | T32GM148331 | PubMed and NIH | NIH RePORTER |
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22683997 | Structural dynamics of the aminoacylation and proofreading functional cycle of bacterial leucyl-tRNA synthetase. | Nat Struct Mol Biol | 2012 | https://conductscience.org/library/papers/22683997 | PubMed |
| 2 | 17588934 | An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. | Science | 2007 | https://conductscience.org/library/papers/17588934 | PubMed |
| 3 | 12384607 | A one-step method for in vitro production of tRNA transcripts. | Nucleic Acids Res | 2002 | https://conductscience.org/library/papers/12384607 | PubMed |
| 4 | 34097493 | In Vitro Profiling of Antitubercular Compounds by Rapid, Efficient, and Nondestructive Assays Using Autoluminescent Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/34097493 | PubMed |
| 5 | 36037447 | Structure-Kinetic Relationship Studies for the Development of Long Residence Time LpxC Inhibitors. | J Med Chem | 2022 | https://conductscience.org/library/papers/36037447 | PubMed |
| 6 | 36454354 | Drug synergy discovery of tavaborole and aminoglycosides against Escherichia coli using high throughput screening. | AMB Express | 2022 | https://conductscience.org/library/papers/36454354 | PubMed |
| 7 | 23959225 | Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase. | Sci Rep | 2013 | https://conductscience.org/library/papers/23959225 | PubMed |
| 8 | 11709357 | Postantibiotic effects of antituberculosis agents alone and in combination. | Antimicrob Agents Chemother | 2001 | https://conductscience.org/library/papers/11709357 | PubMed |
| 9 | 27547299 | Correlating Drug-Target Kinetics and In vivo Pharmacodynamics: Long Residence Time Inhibitors of the FabI Enoyl-ACP Reductase. | Chem Sci | 2016 | https://conductscience.org/library/papers/27547299 | PubMed |
| 10 | 29437618 | In Vitro and In Vivo Activities of DS86760016, a Novel Leucyl-tRNA Synthetase Inhibitor for Gram-Negative Pathogens. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29437618 | PubMed |
| 11 | 38418662 | Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease. | Nat Rev Drug Discov | 2024 | https://conductscience.org/library/papers/38418662 | PubMed |
| 12 | 40170302 | Time-Dependent Inhibition of Leucyl-tRNA-Synthetase (LeuRS): Insight into Target Vulnerability. | ACS Infect Dis | 2025 | https://conductscience.org/library/papers/40170302 | PubMed |
| 13 | 22975201 | Time-dependent, reversible, oxaborole inhibition of Escherichia coli leucyl-tRNA synthetase measured with a continuous fluorescence assay. | Anal Biochem | 2012 | https://conductscience.org/library/papers/22975201 | PubMed |
| 14 | 34637487 | Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline. | PLoS Pathog | 2021 | https://conductscience.org/library/papers/34637487 | PubMed |
| 15 | 28640596 | Drug-Target Kinetics in Drug Discovery. | ACS Chem Neurosci | 2018 | https://conductscience.org/library/papers/28640596 | PubMed |
| 16 | 28953378 | Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). | J Med Chem | 2017 | https://conductscience.org/library/papers/28953378 | PubMed |
| 17 | 27503647 | Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase. | Antimicrob Agents Chemother | 2016 | https://conductscience.org/library/papers/27503647 | PubMed |
| 18 | 19561621 | Absolute metabolite concentrations and implied enzyme active site occupancy in Escherichia coli. | Nat Chem Biol | 2009 | https://conductscience.org/library/papers/19561621 | PubMed |
| 19 | 31030171 | Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics. | Curr Opin Chem Biol | 2019 | https://conductscience.org/library/papers/31030171 | PubMed |
| 20 | 32011855 | Correlating Drug-Target Residence Time and Post-antibiotic Effect: Insight into Target Vulnerability. | ACS Infect Dis | 2020 | https://conductscience.org/library/papers/32011855 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42250658 | The post antibiotic effect of streptogramins on gram-positive bacteria primarily arises from the type a component. | Microb Pathog | 2026 | https://conductscience.org/library/papers/42250658 | PubMed |
| 42018569 | Physiologic recovery of Mycobacterium tuberculosis from drug injury: A molecular study of post antibiotic effect in vitro and in vivo. | PLoS Pathog | 2026 | https://conductscience.org/library/papers/42018569 | PubMed |
Data3
The data bank entries PubMed's record names. Trial numbers are under Trials.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41337752
GET https://conductscience.org/api/papers/v1/41337752/references?page=2